Bitget App
Trade smarter
MarketsTradeFuturesStocksEarnInstitutionAI & More
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.

Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.

路透社路透社2026/10/08 12:56
Show original

The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)

Stock information has been added in the second paragraph, detailed information has been added in the fifth, eighth, and ninth paragraphs, and background information has been added in the sixth, seventh, tenth, and eleventh paragraphs.

- Pharmaceutical company Viatris VTRS.O will acquire Pacira BioSciences PCRX.O in an all-cash deal valued at $1.65 billion, adding two non-opioid pain medications to its portfolio, the two companies announced on Thursday.

Viatris will acquire Pacira for $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s shares rose 44% in premarket trading.

Pacira’s non-opioid pain medications, Exparel and Zilretta,
had 2025 sales of $575.1 million and $116.6 million, respectively. Exparel is used for the treatment of acute post-surgical pain, while Zilretta is used to treat pain associated with knee osteoarthritis.

Viatris said it expects to expand the reach of these products in certain target markets.

Viatris CEO Scott Smith stated in a press release that the addition of these drugs “creates synergy with the market opportunity for our rapid-onset meloxicam and positions us as a leader in the non-opioid pain treatment field.”

The U.S. Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-onset meloxicam to treat moderate to severe acute pain.

Viatris plans to primarily fund this acquisition with available cash, with the remainder raised via short-term borrowing. The company stated the transaction has a minimal impact on its total leverage ratio.

In August, Viatris (link) raised its annual adjusted profit forecast, as it counted on strong sales of branded drugs and growth in the Chinese market.

The pharmaceutical company previously faced setbacks in its Indian operations (link), including manufacturing issues such as a fire at its plant in Nashik, western India, and intensifying competition in the generic drug market, raising concerns over the growth and resilience of its core business.

The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics.



(For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of translated texts. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss that may result from using the automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Updated Version 3 - According to the Financial Times, Starbucks once considered acquiring Chipotle

New charts have been added, providing a detailed overview of Chipotle and Starbucks’ businesses. According to Reuters on October 8, referencing the Financial Times from Thursday, Starbucks had considered acquiring Chipotle Mexican Grill. Such a move would enable CEO Brian Niccol to return to the burrito chain, where he served as chief executive before joining Starbucks two years ago. The Financial Times, citing sources familiar with the matter, reported that the coffee chain has been working with advisers in recent months to formulate an acquisition proposal for Chipotle. Both Starbucks and Chipotle did not immediately respond to Reuters’ requests for comment. Chipotle currently has a market capitalization close to $39 billions, with its stock rising about 6% on Thursday, while Starbucks’ shares fell approximately 3%. According to data from the London Stock Exchange Group (LSEG), Starbucks is valued at about $107 billions. As consumers cut back on discretionary spending, Chipotle has faced declining customer traffic, while rising food and labor costs have pressured profit margins across the sector. Its stock price has dropped about 17% so far this year. Analysts suggest that a potential deal could also accelerate Chipotle’s international expansion. “I see the appeal of this prospective transaction in that CEO Brian Niccol would have the opportunity to leverage Starbucks' European franchise partnerships to pursue Chipotle’s growth more aggressively,” commented Jim Sanderson, an analyst at Northcoast Research. As of the end of last year, Chipotle operated nearly 4,000 restaurants in the US and about 100 abroad. In comparison, Starbucks has about 40,000 stores globally, with roughly 18,000 in North America. Niccol joined Starbucks in 2024 after six years at Chipotle, where he was credited with leading the company’s turnaround following a food safety crisis and with driving several years of strong digital sales growth. He was brought to Starbucks to reverse its declining performance, and over the past two years has focused on improving the customer experience by streamlining menus and reducing wait times, resulting in four consecutive quarters of comparable sales growth. “We still have more work to do,” Niccol said in July, after the company raised its annual sales and profit forecast. “Given that Starbucks is in a period of transformation and has yet to deliver the margin improvements investors expect, the timing of this decision seems somewhat strange. At first glance, it appears to be less about accelerating transformation and more about running out of options,” said Brian Jacobsen, Chief Economist at Annex Wealth Management.

路透社•2026/10/08 15:31

Nvidia plans to invest $1 billion over five years to advance “super intelligence” research in the United States, focusing on quantum computing, healthcare, and energy security.

This investment will be implemented through three pathways: supporting American universities in acquiring computational infrastructure; increasing investment in the field of quantum computing in the United States; and supporting cloud service providers that meet the mission needs of the U.S. government. Jensen Huang stated that this investment will place superintelligent capabilities into the hands of American scientists, "This is the path for the United States to turn scientific leadership into industrial leadership and innovation into employment opportunities."

华尔街见闻•2026/10/08 15:31

SOL falls below 110 USDT, down 5.23% in 24 hours

Odaily星球日报•2026/10/08 15:27

Third Life World signs deal to buy voting control of Transglobal Management Group

Third Life World signed a definitive control share purchase agreement to take voting control of Transglobal Management Group (TMGI). The deal transfers a Series A Preferred control block holding a majority of voting rights to Third Life World. TMGI plans to make Third Life World’s AI-agent virtual world platform its core operating business. TMGI will create new Series B Preferred Stock to support the purchase; closing remains subject to customary conditions. At closing, controlling shareholder Marc Angell will resign his officer roles and stay on as a consultant during the transition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transglobal Management Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081100PRIMZONEFULLFEED9842281) on October 08, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/08 15:00